Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Once Amalgamation is complete...

<< Previous

Bullboard Posts

Next >>

Post by MasterAlgaeon Apr 30, 2021 9:32am

385 Views

Post# 33100203

Once Amalgamation is complete...

it opens up the ability for institutions to invest in the IP of Antibe Therapeutics, whereas without amalgamation there is no IP protection - hence no institutional investors.

I'm thinking that there is some "challenging bargening" going on by the other half of Holdings thinking that they have leverage over A.T. with the stock price dropping each day of no announcement.

America seems to be doing well on The Covid front, but The Covid will be here for a few years to come, so any Covid delays in starting Ph 3 are rapidly diminishing in America.

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal